193 related articles for article (PubMed ID: 9108888)
21. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.
Ao M; Franco OE; Park D; Raman D; Williams K; Hayward SW
Cancer Res; 2007 May; 67(9):4244-53. PubMed ID: 17483336
[TBL] [Abstract][Full Text] [Related]
22. Beta-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor beta 1 action.
Rowley DR; Dang TD; McBride L; Gerdes MJ; Lu B; Larsen M
Cancer Res; 1995 Feb; 55(4):781-6. PubMed ID: 7850789
[TBL] [Abstract][Full Text] [Related]
23. Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II.
Song K; Wang H; Krebs TL; Kim SJ; Danielpour D
Cancer Res; 2008 Oct; 68(19):8173-82. PubMed ID: 18829577
[TBL] [Abstract][Full Text] [Related]
24. Different signals mediate transforming growth factor-beta 1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells.
Franzén P; Ichijo H; Miyazono K
Exp Cell Res; 1993 Jul; 207(1):1-7. PubMed ID: 7686495
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro.
Sehgal I; Baley PA; Thompson TC
Cancer Res; 1996 Jul; 56(14):3359-65. PubMed ID: 8764134
[TBL] [Abstract][Full Text] [Related]
26. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.
Ye SC; Foster JM; Li W; Liang J; Zborowska E; Venkateswarlu S; Gong J; Brattain MG; Willson JK
Cancer Res; 1999 Sep; 59(18):4725-31. PubMed ID: 10493532
[TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
[TBL] [Abstract][Full Text] [Related]
28. A proliferative effect of transforming growth factor-beta1 on a human prostate cancer cell line, TSU-Pr1.
Lamm ML; Sintich SM; Lee C
Endocrinology; 1998 Feb; 139(2):787-90. PubMed ID: 9449654
[TBL] [Abstract][Full Text] [Related]
29. Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer.
Park BJ; Park JI; Byun DS; Park JH; Chi SG
Cancer Res; 2000 Jun; 60(11):3031-8. PubMed ID: 10850453
[TBL] [Abstract][Full Text] [Related]
30. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro.
Wilding G; Zugmeier G; Knabbe C; Flanders K; Gelmann E
Mol Cell Endocrinol; 1989 Mar; 62(1):79-87. PubMed ID: 2545487
[TBL] [Abstract][Full Text] [Related]
31. Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells.
Zhang H; Shaw AR; Mak A; Letarte M
J Immunol; 1996 Jan; 156(2):564-73. PubMed ID: 8543807
[TBL] [Abstract][Full Text] [Related]
32. Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3).
Chen A; Davis BH; Sitrin MD; Brasitus TA; Bissonnette M
Am J Physiol Gastrointest Liver Physiol; 2002 Oct; 283(4):G864-74. PubMed ID: 12223346
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
Yang F; Strand DW; Rowley DR
Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
[TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor-beta1 and prostate cancer.
Wikström P; Bergh A; Damber JE
Scand J Urol Nephrol; 2000 Apr; 34(2):85-94. PubMed ID: 10903068
[TBL] [Abstract][Full Text] [Related]
35. Transforming growth factor-beta in breast cancer: a working hypothesis.
Reiss M; Barcellos-Hoff MH
Breast Cancer Res Treat; 1997 Aug; 45(1):81-95. PubMed ID: 9285120
[TBL] [Abstract][Full Text] [Related]
36. ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells.
Noda D; Itoh S; Watanabe Y; Inamitsu M; Dennler S; Itoh F; Koike S; Danielpour D; ten Dijke P; Kato M
Oncogene; 2006 Sep; 25(41):5591-600. PubMed ID: 16636667
[TBL] [Abstract][Full Text] [Related]
37. Modulation of sensitivity to transforming growth factor-beta 1 (TGF-beta 1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone.
Kim IY; Zelner DJ; Sensibar JA; Ahn HJ; Park L; Kim JH; Lee C
Exp Cell Res; 1996 Jan; 222(1):103-10. PubMed ID: 8549651
[TBL] [Abstract][Full Text] [Related]
38. Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells.
Bruckheimer EM; Kyprianou N
Endocrinology; 2001 Jun; 142(6):2419-26. PubMed ID: 11356690
[TBL] [Abstract][Full Text] [Related]
39. Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue.
Eklöv S; Funa K; Nordgren H; Olofsson A; Kanzaki T; Miyazono K; Nilsson S
Cancer Res; 1993 Jul; 53(13):3193-7. PubMed ID: 7686449
[TBL] [Abstract][Full Text] [Related]
40. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.
Baldwin RL; Tran H; Karlan BY
Cancer Res; 2003 Mar; 63(6):1413-9. PubMed ID: 12649207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
